Louis Lombardo is a Partner at MSF. Mr. Lombardo provides corporate and securities law advice to clients in mergers and acquisitions, corporate governance, public and private securities offering and other transactional matters across a variety of industries, including technology, media, life sciences, consumer products and manufacturing. Mr. Lombardo regularly represents senior management, corporate boards, strategic market participants and investment funds with respect to mergers, acquisitions, dispositions, joint ventures and other complex business transactions, as well as public and private issuers and investors in equity and debt financing transactions. Mr. Lombardo also has extensive experience representing clients in life science transactional matters including licensing, development collaborations, co-promotion arrangements, asset acquisition and disposition and financing.
Brooklyn Law School. J.D.
Wagner College. B.S
State of New York
State of New Jersey
Before joining MSF in 2016, Mr. Lombardo was a principal of Lombardo Dufresne LLP, a boutique corporate transactional law firm that he co-founded in 2006, and served as Deputy General Counsel to a biopharmaceutical company which he helped found in 2009. Prior to 2006, Mr. Lombardo was Counsel in the Corporate and Finance Group of Kaye Scholer LLP, New York, New York
Represented a New York-based biotechnology company in its resale registration statement for selling stockholders.
Represented a New York-based private company in its $200 million acquisition of a Pennsylvania-based pharmaceutical company.
Represented a New York-based importing company in its $2.2 billion divestiture of a premier high-strength spirit brand.
Represented the shareholders in their $6.5 million divestiture of a New Jersey-based access systems integrator.
Represented a New-York-based technology company in its $35 million senior credit facility.
Represented a Florida-based publicly traded company in its $6 million acquisition of low power TV stations from Viacom.
Represented a New York-based risk management software company in its $23 million merger with a major, privately-held data software company.
Represented a New York-based biotech company in its worldwide license of a clinical stage small molecule (multi-tyrosine kinase inhibitor) and all of the related intellectual property from a New York-based biotech investment fund.
Represented a New York-based biotech company in connection with $135 million senior credit facility and $65 million senior convertible credit facility with a syndicate of lenders.
Represented a New York-based private real estate fund in connection with a $100 million senior credit facility with national banking institution.